Celgene Announces Statistical Significance for Primary, Secondary Endpoints in Phase II Trial in Patients with Behçet's Disease

Celgene International Sàrl, a subsidiary of Celgene Corporation

today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease (BD) at EULAR, the European Congress of Rheumatology annual meeting in Madrid. The Company announced statistical significance for the primary endpoint of the mean number of oral ulcers at week 12 (APR 30 mg BID, 0.5; PBO, 2.1; p<0.0001) evaluating the Company's novel, oral small-molecule inhibitor of phophodiesterase 4 (PDE4) in patients with Behcet's disease. The complete response rate (oral ulcer free) at week 12 was also statistically significant (APR, 71%; PBO, 29%; p<0.0001). Statistically significant and clinically meaningful responses were demonstrated across all secondary endpoints, including all patient-reported outcomes.